Hikma Pharmaceuticals (LON: HIK), the UK-headquartered maker of branded and non-branded generic medicines, said earlier today that Rebecca “Becky” Hall will become its next Chief Financial Officer and join the board as an Executive Director. Hall is currently Senior Vice President and Chief Financial Officer of ViiV Healthcare, the global specialist HIV pharmaceutical company majority owned by GSK, with Shionogi as a shareholder, where she oversees finance, supply chain and business development. She is due to join Hikma in the first quarter of 2027, with the exact start date still to be confirmed.
Hikma shares stood at 1596p, barely changed from Wednesday’s close of 1595p. The appointment is a governance move rather than a trading catalyst, and the flat price should not be read as a market reaction to the news.
Hall has spent more than 20 years across GSK and ViiV, where 2025 revenue reached close to £8 billion with 11% growth. Her career has spanned London, the United States, where she led ViiV’s North America finance team, and Singapore, where she ran supply chain finance across Asia Pacific, Latin America, the Middle East and North Africa.
Chief executive Said Darwazah welcomed the appointment and thanked Areb Kurdi, who has served as Acting CFO and will continue in that role until Hall arrives. Darwazah described Hall as an accomplished pharmaceutical leader whose broad operational experience and financial discipline would support delivery of Hikma’s strategic plans.
Chair Victoria Hull said the appointment broadens expertise across the executive team and the board, positioning Hikma for long-term sustainable growth. Hall replaces Khalid Nabilsi as Executive Director; he steps down from the board on the 31st of December 2026 but remains Deputy CEO for North America and Europe on the executive committee.
Hall pointed to Hikma’s 45-year record of making medicines accessible worldwide, saying she looked forward to helping deliver its growth ambitions for patients, shareholders and colleagues. She joins the board when she starts in the first quarter of 2027.